Cardiology

PRONOUNCE: Relative cardiovascular safety of GnRH antagonists vs agonists still unresolved

2 days ago

The gonadotropin-releasing hormone (GnRH) antagonist degarelix and the GnRH agonist leuprolide appear to be similar in terms of the rate of cardiovascular events in a cohort of patients with prostate cancer, according to the results of the PRONOUNCE trial.

Molnupiravir pill: A game-changer in COVID-19?

Pearl Toh, 2 days ago

The investigational oral antiviral pill molnupiravir significantly slashed the risk of hospitalization or death by half in nonhospitalized adults with mild-to-moderate COVID-19, according to interim data from the phase III MOVe-OUT trial.

Higher serum uric acid translates to greater CV disease burden in chronic coronary syndromes

2 days ago

Among patients with chronic coronary syndromes, those with higher serum uric acid (SUA) levels are more likely to have major adverse cardiovascular (CV) events (MACE) and worse related quality of life (QoL), as reported in a study.

Health status similar between sacubitril/valsartan and ramipril recipients post-acute MI

Roshini Claire Anthony, 3 days ago

Patients who receive sacubitril-valsartan after an acute myocardial infarction (MI) have a similar health status, as determined by EQ-5D visual analog scale (VAS) score, compared with those who receive ramipril, according to results of a prespecified analysis of the PARADISE-MI trial presented at HFSA 2021.

Genotype-guided platelet inhibition improves STEMI outcomes

4 days ago

Bedside genotype testing for mutations in the CYP2C19 gene helps select a better P2Y12 inhibitor treatment strategy for patients with ST-segment elevation myocardial infarction (STEMI) and leads to better outcomes relative to conventional therapy, a recent study has found.

Trimetazidine new formulation redefining angina control in daily practice

12 Mar 2021

Chronic coronary syndrome (CCS) remains a leading cause of death and disability worldwide. The dual goals of CCS management is to prevent future cardiac events, such as myocardial infarction and death, and to reduce ischaemia and relieve angina symptoms, says Prof Peter Yan, consultant cardiologist and medical director, Peter Yan Cardiology Clinic, Gleneagles Medical Centre, Singapore, during a Servier-sponsored virtual symposium.

Empagliflozin not just another SGLT2i: Cardio-renal benefits extend to HF with or without diabetes

Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Empagliflozin: Another SGLT-2i in HFrEF armamentarium

Roshini Claire Anthony, 05 Nov 2020

Adding empagliflozin to recommended therapy in patients with heart failure with reduced ejection fraction (HFrEF) reduced the risk of HF hospitalization and slowed renal function decline, the EMPEROR-Reduced* trial showed.

Empagliflozin advancing on all fronts: Readying for the future with EMPEROR

11 Aug 2020

In this final issue of our series, join us as we look into the upcoming results of the pivotal EMPEROR trials, which will investigate the use of empagliflozin in patients with either preserved or reduced ejection fraction heart failure, with or without type 2 diabetes. Understand why heart failure has such a high clinical burden, and the great unmet need in providing solutions for it.

Health status similar between sacubitril/valsartan and ramipril recipients post-acute MI

Roshini Claire Anthony, 23 Oct 2021

Abnormal nighttime BP doubles death risk in diabetes patients

Pearl Toh, 14 Oct 2021

For adults with diabetes, increased blood pressure (BP) at night (reverse dipping) was associated with more than double the risk of death compared with those whose BP dipped as expected at night, according to the longitudinal CHAMP1ON study presented at Hypertension 2021.

Dapagliflozin improves symptoms, physical limitations in HFpEF

Roshini Claire Anthony, 13 Oct 2021

Patients with heart failure and preserved ejection fraction (HFpEF) treated with dapagliflozin experienced improvements in symptoms and physical limitations, according to results of the PRESERVED-HF study presented at HFSA 2021.

Assessing orthostatic hypotension: Supine vs seated BP?

Pearl Toh, 11 Oct 2021

When assessing for orthostatic hypotension, lying supine rather than sitting before switching to a standing position better detects orthostatic symptoms and is more predictive of falls among older adults at high risk of falls, according to the STURDY* trial presented at Hypertension 2021.

CV safety of degarelix vs leuprolide: Results remain inconclusive

Roshini Claire Anthony, 06 Oct 2021

In men with prostate cancer and concomitant atherosclerotic cardiovascular disease (ASCVD), major adverse cardiovascular event (MACE) incidence did not differ between those who were treated with degarelix or leuprolide, according to findings of the PRONOUNCE trial.

1-month DAPT may be enough post-PCI

Elvira Manzano, 06 Oct 2021

In patients at high-bleeding risk (HBR) implanted with a drug-eluting coronary stent, 1 month of dual antiplatelet therapy (DAPT) is as good as 3 months or longer – with significantly less bleeding – in the MASTER DAPT* trial, that experts said shorter DAPT post coronary stenting may be the strategy moving forward.

Finerenone CV benefit extends to wide spectrum of CKD patients with T2D: FIGARO-DKD

Pearl Toh, 25 Sep 2021

The large, phase III FIGARO-DKD trial strengthen the evidence on cardiovascular benefit (CV) of the nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone, in addition to its renal benefit, across a wide spectrum of patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).